No Unwanted Immune Responses Found for SMA Children on Spinraza
Spinraza (nusinersen) treatment is safe in children with spinal muscular atrophy (SMA) and does not cause unwanted immune…
Articles by Steve Bryson, PhD
In Real World, Adherence Low to Spinraza Treatment, Data Show
A significant proportion of people with spinal muscular atrophy (SMA) do not remain on Spinraza (nusinersen) or receive…
Long-term Breathing Help in SMA Rose in Last 10 Years in UK: Survey
The use of long-term breathing help, or ventilation, has markedly increased among children with spinal muscular atrophy (SMA) type…
Prenatal Blood Test Accurately Gauges SMA Risk
UNITY Screen, a noninvasive prenatal blood test, can provide an accurate personalized risk assessment for hereditary diseases such as…
Cell Death Protein Marks Vulnerable Nerve Cells in 2 SMA Mouse Models
The elevated production of the cell-death-related protein c-Fos was closely linked to the death of motor neurons in two mouse…
Scoliosis Progression Detailed in Untreated SMA Type 2 Children
Severe scoliosis — an abnormal curvature of the spine — was significantly associated with older age and limited motor abilities…
Risk Factors ID’d That Predict Lung Infection, Lung Failure in Children
Disease subtype, low body fat content, and shallow breathing and low blood oxygen levels during sleep are risk factors for…
Most SMA Patients Unaware of SMN2 Copy Number, Survey Says
Most people with spinal muscular atrophy (SMA) are unaware of their SMN2 copy number, and in a few cases,…
Long-term Spinraza Treatment Found to Help SMA Teens, Adults
Up to 4.5 years of Spinraza (nusinersen) treatment led to meaningful improvements in motor function in adolescents and adults…
Lack of Suspicion by Doctors May Lead to Delayed Diagnosis in SMA
A delayed diagnosis in spinal muscular atrophy (SMA) may occur in many cases due to the absence of clinical…